We hypothesize that SETD2-deficient cancer may be more sensitive to the inactivation of ASF1A and ASF1B than SETD2-proficient cancer if SETD2 loss–induced increase in histone exchange is required for creating a permissive epigenetic landscape to enhance oncogenic transcriptional output. This evidence concerns the gene SETD2 and cancer.